Horvath Philipp, Yurttas Can, Beckert Stefan, Königsrainer Alfred, Königsrainer Ingmar
Comprehensive Cancer Center, Department of General, Visceral and Transplant Surgery, University of Tübingen, 72076 Tübingen, Germany.
Department of General and Visceral Surgery, Schwarzwald-Baar Klinikum, 78052 Villingen-Schwenningen, Germany.
Cancers (Basel). 2021 May 19;13(10):2471. doi: 10.3390/cancers13102471.
(1) : Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy provide survival benefits to selected patients. We aimed to report our experience and the evolution of our peritoneal surface malignancy program. (2) : From June 2005 to June 2017, 399 patients who underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy at the Tübingen University Hospital were analyzed from a prospectively collected database. (3) : Peritoneal metastasis from colorectal cancer was the leading indication (group 1: 28%; group 2: 32%). The median PCI was 15.5 (range, 1-39) in group 1 and 11 (range, 1-39) in group 2 ( = 0.002). Regarding the completeness of cytoreduction (CC), a score of 0 was achieved in 63% vs. 69% for group 1 and 2, respectively ( = 0.010). Median overall survival rates for patients in group 1 and 2 for colon cancer, ovarian cancer, gastric cancer and appendix cancer were 34 and 25 months; 45 months and not reached; 30 and 16 months; 39 months and not reached, respectively. The occurrence of grade-III and -IV complications slightly differed between groups (14.5% vs. 15.6%). No 30-day mortality occurred. (4) : Specialized centers are able to provide low-morbidity cytoreductive surgery and hyperthermic intraperitoneal chemotherapy without mortality. Strict patient selection during the time period significantly improved CC scores.
(1)：细胞减灭术和腹腔内热灌注化疗为特定患者带来生存益处。我们旨在报告我们的经验以及我们腹膜表面恶性肿瘤治疗方案的演变。(2)：从2005年6月至2017年6月，对图宾根大学医院399例行细胞减灭术加腹腔内热灌注化疗的患者，从一个前瞻性收集的数据库进行分析。(3)：结直肠癌腹膜转移是主要指征（第1组：28%；第2组：32%）。第1组的中位腹膜癌指数（PCI）为15.5（范围1 - 39），第2组为11（范围1 - 39）（P = 0.002）。关于细胞减灭的完整性（CC），第1组和第2组分别有63%和69%达到0分（P = 0.010）。第1组和第2组结肠癌、卵巢癌、胃癌和阑尾癌患者的中位总生存率分别为34个月和25个月；45个月和未达到；30个月和16个月；39个月和未达到。III级和IV级并发症的发生率在两组间略有差异（14.5%对15.6%）。未发生30天死亡率。(4)：专业中心能够提供低发病率的细胞减灭术和腹腔内热灌注化疗且无死亡率。在此期间严格的患者选择显著提高了CC评分。
